Next Article in Journal
National and Subnational Population-Based Incidence of Cancer in Thailand: Assessing Cancers with the Highest Burdens
Next Article in Special Issue
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Previous Article in Journal / Special Issue
ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Cancers 2017, 9(8), 107; https://doi.org/10.3390/cancers9080107

ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice

1
Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, 30 avenue de la voie romaine, 06001 Nice cedex 01, France
2
FHU OncoAge, Côte d’Azur University, 30 avenue de la voie romaine, 06001 Nice cedex 01, France
3
Hospital-integrated Biobank (BB-0033-00025), 30 avenue de la voie romaine, 06001 Nice cedex 01, France
Academic Editor: Raymond Lai
Received: 17 July 2017 / Revised: 8 August 2017 / Accepted: 10 August 2017 / Published: 12 August 2017
(This article belongs to the Special Issue Targeting ALK in Cancer)
View Full-Text   |   Download PDF [626 KB, uploaded 14 August 2017]   |  

Abstract

Patients with advanced-stage non-small cell lung carcinoma (NSCLC) harboring an ALK rearrangement, detected from a tissue sample, can benefit from targeted ALK inhibitor treatment. Several increasingly effective ALK inhibitors are now available for treatment of patients. However, despite an initial favorable response to treatment, in most cases relapse or progression occurs due to resistance mechanisms mainly caused by mutations in the tyrosine kinase domain of ALK. The detection of an ALK rearrangement is pivotal and can be done using different methods, which have variable sensitivity and specificity depending, in particular, on the quality and quantity of the patient’s sample. This review will first highlight briefly some information regarding the pathobiology of an ALK rearrangement and the epidemiology of patients harboring this genomic alteration. The different methods used to detect an ALK rearrangement as well as their advantages and disadvantages will then be examined and algorithms proposed for detection in daily routine practice. View Full-Text
Keywords: ALK rearrangement, lung cancer, biology, immunohistochemistry, FISH, molecular biology. ALK rearrangement, lung cancer, biology, immunohistochemistry, FISH, molecular biology.
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Hofman, P. ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice. Cancers 2017, 9, 107.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top